Hochhauser Edith, Pappo Orit, Ribakovsky Evgeni, Ravid Amiram, Kurtzwald Efrat, Cheporko Yelena, Lelchuk Shlomo, Ben-Ari Ziv
Cardiac Research Laboratory of Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petah Tiqva and Sackler School of Medicine,Tel Aviv University, Tel Aviv, Israel.
Apoptosis. 2008 Jan;13(1):77-86. doi: 10.1007/s10495-007-0155-8.
Apoptosis is a central mechanism of cell death following reperfusion of the ischemic liver. Recombinant human erythropoietin (rhEPO) have an important role in the treatment of myocardial ischemia/reperfusion (I/R) injury, by preventing apoptosis. The aim of the study was to investigate the effect of different regimens of rhEPO in preventing apoptosis following I/R-induced hepatic injury.
Isolated mouse livers were randomly divided into five groups: (1) control group, perfused for the whole study period (105 min); (2) 30-min perfusion followed by 90 min of ischemia and 15 min of reperfusion; (3), (4) and (5) like group 2, but with administration of rhEPO 5,000 units/kg i.p. at 30 min, 24 h, or both 30 min and 24 h respectively, before induction of ischemia. Perfusate liver enzyme levels and intrahepatic caspase-3 activity were measured, and apoptotic cells were identified by morphological criteria, TUNEL assay, and immunohistochemistry for caspase-3. Using immunoblot the expression of the proapoptotic JNK and inhibitor of NFkappaB (IkappaBalpha) were also evaluated. von Willebrand factor (vWF) immunohistochemistry was used as a marker of endothelial cells.
Compared to the I/R livers, all 3 rhEPO pretreated groups showed: a significant reduction in liver enzyme levels (P < 0.05) and intrahepatic caspase-3 activity (P < 0.05), fewer apoptotic hepatocytes (P < 0.05) and positive vWF staining in numerous endothelial cells lining the sinusoids. EPO decreased JNK phosphorylation and the degradation of the inhibitor of NFkappaB (IkappaBalpha) during I/R. There was no added benefit of the multiple- over the single-dose rhEPO regimen.
Pretreatment with one dose of rhEPO can attenuate post-I/R hepatocyte apoptotic liver damage. NFkappaB and JNK activation is likely to play a pivotal role in the pathophysiology of I/R hepatic injury and might have a key role in EPO-mediated protective effects. This effect is associated with the increase in sinusoidal vWF immunostaining suggests an additional effect of rhEPO in liver angiogenesis recovery. These findings have important implications for the potential use of rhEPO in I/R injury during liver transplantation.
细胞凋亡是缺血肝脏再灌注后细胞死亡的核心机制。重组人促红细胞生成素(rhEPO)通过预防细胞凋亡在心肌缺血/再灌注(I/R)损伤的治疗中发挥重要作用。本研究的目的是探讨不同方案的rhEPO对预防I/R诱导的肝损伤后细胞凋亡的影响。
将分离的小鼠肝脏随机分为五组:(1)对照组,在整个研究期间(105分钟)进行灌注;(2)灌注30分钟,随后缺血90分钟和再灌注15分钟;(3)、(4)和(5)组与第2组相似,但在缺血诱导前分别于30分钟、24小时或30分钟和24小时同时腹腔注射rhEPO 5000单位/千克。测量灌注液肝酶水平和肝内caspase-3活性,并通过形态学标准、TUNEL检测和caspase-3免疫组织化学鉴定凋亡细胞。使用免疫印迹法还评估了促凋亡JNK和核因子κB抑制剂(IkappaBalpha)的表达。采用血管性血友病因子(vWF)免疫组织化学作为内皮细胞的标志物。
与I/R肝脏相比,所有3个rhEPO预处理组均显示:肝酶水平(P < 0.05)和肝内caspase-3活性显著降低(P < 0.05),凋亡肝细胞减少(P < 0.05),并且在许多肝血窦内皮细胞中vWF染色呈阳性。EPO在I/R期间降低了JNK磷酸化和核因子κB抑制剂(IkappaBalpha)的降解。多剂量rhEPO方案与单剂量方案相比没有额外的益处。
一剂rhEPO预处理可减轻I/R后肝细胞凋亡性肝损伤。核因子κB和JNK激活可能在I/R肝损伤的病理生理学中起关键作用,并且可能在EPO介导的保护作用中起关键作用。这种作用与肝血窦vWF免疫染色增加相关,提示rhEPO在肝血管生成恢复中具有额外作用。这些发现对rhEPO在肝移植I/R损伤中的潜在应用具有重要意义。